1. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques
- Author
-
Lulu Huang, Tongyi Zhao, Weijun Zhao, Andong Shao, Huajun Zhao, Wenxuan Ma, Yingfei Gong, Xianhuan Zeng, Changzhen Weng, Lingling Bu, Zhenhua Di, Shiyu Sun, Qinsheng Dai, Minhui Sun, Limei Wang, Zhenguang Liu, Leilei Shi, Jiesen Hu, Shentong Fang, Cheng Zhang, Jian Zhang, Guan Wang, Karin Loré, Yong Yang, and Ang Lin
- Subjects
Varicella Zoster Virus ,mRNA vaccine ,Shingrix ,nonhuman primate ,immune mechanisms ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
ABSTRACTHerpes zoster remains an important global health issue and mainly occurs in aged and immunocompromised individuals with an early exposure history to Varicella Zoster Virus (VZV). Although the licensed vaccine Shingrix has remarkably high efficacy, undesired reactogenicity and increasing global demand causing vaccine shortage urged the development of improved or novel VZV vaccines. In this study, we developed a novel VZV mRNA vaccine candidate (named as ZOSAL) containing sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated in an ionizable lipid nanoparticle. In mice and rhesus macaques, ZOSAL demonstrated superior immunogenicity and safety in multiple aspects over Shingrix, especially in the induction of strong T-cell immunity. Transcriptomic analysis revealed that both ZOSAL and Shingrix could robustly activate innate immune compartments, especially Type-I IFN signalling and antigen processing/presentation. Multivariate correlation analysis further identified several early factors of innate compartments that can predict the magnitude of T-cell responses, which further increased our understanding of the mode of action of two different VZV vaccine modalities. Collectively, our data demonstrated the superiority of VZV mRNA vaccine over licensed subunit vaccine. The mRNA platform therefore holds prospects for further investigations in next-generation VZV vaccine development.
- Published
- 2024
- Full Text
- View/download PDF